STOK
Stoke Therapeutics, Inc.
Price Chart
Latest Quote
$31.00
+0.74 (+2.45%)
Current Price
| Previous Close | $30.26 |
| Open | $30.92 |
| Day High | $31.49 |
| Day Low | $29.84 |
| Volume | 1,946,300 |
Stock Information
| Shares Outstanding | 62.28M |
| Total Debt | $3.42M |
| Cash Equivalents | $343.54M |
| Revenue | $32.08M |
| Net Income | $-169.77M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.93B |
| EPS (TTM) | $-2.86 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.48B |
| Sales | $32.08M |
| Income | $-169.77M |
| Book/sh | $6.34 |
| Cash/sh | $5.52 |
| Employees | 170 |
Financial Ratios
| Quick Ratio | 8.57 |
| Current Ratio | 8.99 |
| Debt/Eq | 0.87 |
Returns & Margins
| ROA | -27.24% |
| ROE | -45.58% |
| Gross Margin | 100.00% |
| Operating Margin | -857.57% |
Ownership
| Insider Ownership | 3.82% |
| Institutional Ownership | 120.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.99 |
| P/S | 60.18 |
| P/B | 4.89 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $45.10 |
Technical Indicators
| SMA20 | $29.96 |
| SMA50 | $32.07 |
| SMA200 | $30.74 |
| RSI | 50.44 |
| ATR | 1.4996 |
| Shares Float | 46.76M |
| Short Float | 18.75% |
| Short Ratio | 20.24 |
| Volatility | 1.19 |
| Rel Volume | 3.26 |
Performance History
| Week | +5.59% |
| Month | +3.47% |
| Quarter | -6.60% |
| 6 Months | -7.77% |
| YTD | +0.32% |
| Year | +165.87% |
| 3 Years | +148.80% |
| 5 Years | -17.79% |
| 10 Years | +21.24% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $31.00 | 1,971,100 |
| 2026-06-17 | $30.26 | 955,200 |
| 2026-06-16 | $29.15 | 410,700 |
| 2026-06-15 | $30.00 | 833,900 |
| 2026-06-12 | $29.82 | 478,900 |
| 2026-06-11 | $29.36 | 498,400 |
| 2026-06-10 | $28.48 | 534,000 |
| 2026-06-09 | $29.37 | 453,600 |
| 2026-06-08 | $29.00 | 331,400 |
| 2026-06-05 | $30.01 | 569,500 |
| 2026-06-04 | $30.12 | 595,500 |
| 2026-06-03 | $29.46 | 449,800 |
| 2026-06-02 | $28.68 | 611,400 |
| 2026-06-01 | $30.47 | 467,600 |
| 2026-05-29 | $30.91 | 543,800 |
| 2026-05-28 | $31.61 | 386,000 |
| 2026-05-27 | $31.45 | 359,100 |
| 2026-05-26 | $31.03 | 478,400 |
| 2026-05-22 | $29.34 | 682,800 |
| 2026-05-21 | $29.67 | 488,000 |
| 2026-05-20 | $30.30 | 950,600 |
| 2026-05-19 | $29.96 | 704,600 |
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
đ° Latest News
4 Biotech Stocks Investors Should Watch in 2026
Zacks âĸ 2026-06-05T14:54:00Z
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks âĸ 2026-06-04T13:55:02Z
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates
Insider Monkey âĸ 2026-06-01T08:02:27Z
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
Simply Wall St. âĸ 2026-05-11T13:33:24Z
Stoke Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-09T04:07:06Z
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T23:05:10Z
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-06T11:45:05Z
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus
Simply Wall St. âĸ 2026-04-06T17:09:20Z
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
BioPharma Dive âĸ 2026-04-01T17:15:00Z
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
Motley Fool âĸ 2026-03-28T00:52:22Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $184,420,000 | $36,555,000 | $8,780,000 | $12,405,000 |
| Operating Revenue | $184,420,000 | $36,555,000 | $8,780,000 | $12,405,000 |
| Expenses | ||||
| Total Expenses | $205,010,000 | $137,927,000 | $123,553,000 | $116,761,000 |
| Other Income Expense | $-51,000 | $-247,000 | $166,000 | $167,000 |
| Other Non Operating Income Expenses | $-51,000 | $-247,000 | $166,000 | $167,000 |
| Net Non Operating Interest Income Expense | $13,756,000 | $12,638,000 | $9,908,000 | $3,122,000 |
| Total Other Finance Cost | $-13,756,000 | $-12,638,000 | $-9,908,000 | $-3,122,000 |
| Operating Expense | $205,010,000 | $137,927,000 | $123,553,000 | $116,761,000 |
| General And Administrative Expense | $67,088,000 | $48,794,000 | $41,322,000 | $38,924,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Net Interest Income | $13,756,000 | $12,638,000 | $9,908,000 | $3,122,000 |
| Normalized Income | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Net Income From Continuing And Discontinued Operation | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Total Operating Income As Reported | $-20,590,000 | $-101,372,000 | $-114,773,000 | $-104,356,000 |
| Net Income Common Stockholders | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Net Income | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Net Income Including Noncontrolling Interests | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Net Income Continuous Operations | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Pretax Income | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Operating Income | $-20,590,000 | $-101,372,000 | $-114,773,000 | $-104,356,000 |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.12 | $-1.65 | $-2.38 | $-2.60 |
| Basic EPS | $-0.12 | $-1.65 | $-2.38 | $-2.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-18,820,000 | $-99,195,000 | $-112,304,000 | $-102,810,000 |
| Reconciled Depreciation | $1,770,000 | $2,177,000 | $2,469,000 | $1,546,000 |
| EBITDA (Bullshit earnings) | $-18,820,000 | $-99,195,000 | $-112,304,000 | $-102,810,000 |
| EBIT | $-20,590,000 | $-101,372,000 | $-114,773,000 | $-104,356,000 |
| Diluted Average Shares | $59,219,184 | $54,008,883 | $43,994,862 | $38,897,442 |
| Basic Average Shares | $59,219,184 | $54,008,883 | $43,994,862 | $38,897,442 |
| Diluted NI Availto Com Stockholders | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
| Research And Development | $137,922,000 | $89,133,000 | $82,231,000 | $77,837,000 |
| Selling General And Administration | $67,088,000 | $48,794,000 | $41,322,000 | $38,924,000 |
| Other Gand A | $67,088,000 | $48,794,000 | $41,322,000 | $38,924,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $352,457,000 | $229,021,000 | $159,565,000 | $184,849,000 |
| Total Assets | $418,434,000 | $271,555,000 | $228,342,000 | $256,067,000 |
| Total Non Current Assets | $112,734,000 | $38,799,000 | $13,003,000 | $11,997,000 |
| Other Non Current Assets | $227,000 | $721,000 | $569,000 | $569,000 |
| Investmentin Financial Assets | $106,260,000 | $29,824,000 | $0 | - |
| Current Assets | $305,700,000 | $232,756,000 | $215,339,000 | $244,070,000 |
| Other Current Assets | $3,895,000 | $2,297,000 | $2,561,000 | $2,955,000 |
| Restricted Cash | $494,000 | $75,000 | $0 | - |
| Prepaid Assets | $8,736,000 | $11,117,000 | $11,320,000 | $10,932,000 |
| Receivables | $7,905,000 | $2,368,000 | $64,000 | $588,000 |
| Accrued Interest Receivable | $1,969,000 | $700,000 | $64,000 | $588,000 |
| Accounts Receivable | $5,936,000 | $1,668,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $284,670,000 | $216,899,000 | $201,394,000 | $229,595,000 |
| Cash And Cash Equivalents | $84,220,000 | $127,983,000 | $191,442,000 | $113,556,000 |
| Cash Equivalents | - | - | $191,442,000 | $113,556,000 |
| Current Deferred Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $3,007,000 | $2,322,000 | $2,062,000 | $2,359,000 |
| Current Debt And Capital Lease Obligation | $3,007,000 | $2,322,000 | $2,062,000 | $2,359,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $65,977,000 | $42,534,000 | $68,777,000 | $71,218,000 |
| Total Non Current Liabilities Net Minority Interest | $8,102,000 | $2,478,000 | $37,958,000 | $39,824,000 |
| Other Non Current Liabilities | $1,141,000 | $2,478,000 | $4,884,000 | $2,968,000 |
| Non Current Deferred Liabilities | $6,961,000 | $0 | $33,074,000 | $36,856,000 |
| Current Liabilities | $57,875,000 | $40,056,000 | $30,819,000 | $31,394,000 |
| Other Current Liabilities | $1,060,000 | $753,000 | $857,000 | $509,000 |
| Current Deferred Liabilities | $11,901,000 | $18,991,000 | $15,309,000 | $14,880,000 |
| Payables And Accrued Expenses | $27,932,000 | $10,304,000 | $6,980,000 | $7,892,000 |
| Payables | $4,939,000 | $2,498,000 | $1,695,000 | $766,000 |
| Accounts Payable | $4,939,000 | $2,498,000 | $1,695,000 | $766,000 |
| Equity | ||||
| Common Stock Equity | $352,457,000 | $229,021,000 | $159,565,000 | $184,849,000 |
| Total Equity Gross Minority Interest | $352,457,000 | $229,021,000 | $159,565,000 | $184,849,000 |
| Stockholders Equity | $352,457,000 | $229,021,000 | $159,565,000 | $184,849,000 |
| Gains Losses Not Affecting Retained Earnings | $543,000 | $-151,000 | $-24,000 | $-1,175,000 |
| Other Equity Adjustments | $543,000 | $-151,000 | $-24,000 | $-1,175,000 |
| Retained Earnings | $-497,715,000 | $-490,830,000 | $-401,849,000 | $-297,150,000 |
| Other | ||||
| Ordinary Shares Number | $58,921,999 | $54,032,826 | $45,918,233 | $39,439,575 |
| Share Issued | $58,921,999 | $54,032,826 | $45,918,233 | $39,439,575 |
| Tangible Book Value | $352,457,000 | $229,021,000 | $159,565,000 | $184,849,000 |
| Invested Capital | $352,457,000 | $229,021,000 | $159,565,000 | $184,849,000 |
| Working Capital | $247,825,000 | $192,700,000 | $184,520,000 | $212,676,000 |
| Capital Lease Obligations | $3,007,000 | $2,322,000 | $2,062,000 | $2,359,000 |
| Total Capitalization | $352,457,000 | $229,021,000 | $159,565,000 | $184,849,000 |
| Additional Paid In Capital | $849,624,000 | $719,997,000 | $561,433,000 | $483,170,000 |
| Capital Stock | $5,000 | $5,000 | $5,000 | $4,000 |
| Common Stock | $5,000 | $5,000 | $5,000 | $4,000 |
| Non Current Deferred Revenue | $6,961,000 | $0 | $33,074,000 | $36,856,000 |
| Current Deferred Revenue | $11,901,000 | $18,991,000 | $15,309,000 | $14,880,000 |
| Current Capital Lease Obligation | $3,007,000 | $2,322,000 | $2,062,000 | $2,359,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $13,975,000 | $7,686,000 | $5,611,000 | $5,754,000 |
| Current Accrued Expenses | $22,993,000 | $7,806,000 | $5,285,000 | $7,126,000 |
| Investments And Advances | $106,260,000 | $29,824,000 | $0 | - |
| Available For Sale Securities | $106,260,000 | $29,824,000 | - | - |
| Net PPE | $6,247,000 | $8,254,000 | $12,434,000 | $11,428,000 |
| Accumulated Depreciation | $-10,146,000 | $-8,848,000 | $-6,671,000 | $-4,207,000 |
| Gross PPE | $16,393,000 | $17,102,000 | $19,105,000 | $15,635,000 |
| Leases | $2,213,000 | $2,329,000 | $2,294,000 | $1,867,000 |
| Construction In Progress | $615,000 | $120,000 | $65,000 | $447,000 |
| Other Properties | $12,771,000 | $13,859,000 | $15,994,000 | $12,656,000 |
| Machinery Furniture Equipment | $794,000 | $794,000 | $752,000 | $665,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $200,450,000 | $88,916,000 | $9,952,000 | $116,039,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $44,915,000 | $-87,054,000 | $-82,683,000 | $-35,828,000 |
| Operating Activities | ||||
| Operating Cash Flow | $45,585,000 | $-86,851,000 | $-81,067,000 | $-31,866,000 |
| Cash Flow From Continuing Operating Activities | $45,585,000 | $-86,851,000 | $-81,067,000 | $-31,866,000 |
| Operating Gains Losses | $145,000 | - | $1,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-670,000 | $-203,000 | $-1,616,000 | $-3,962,000 |
| Investing Cash Flow | $-186,812,000 | $-107,475,000 | $105,946,000 | $-45,882,000 |
| Cash Flow From Continuing Investing Activities | $-186,812,000 | $-107,475,000 | $105,946,000 | $-45,882,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $87,784,000 | $128,840,000 | $52,081,000 | $45,344,000 |
| Financing Cash Flow | $97,389,000 | $131,094,000 | $53,007,000 | $46,409,000 |
| Cash Flow From Continuing Financing Activities | $97,389,000 | $131,094,000 | $53,007,000 | $46,409,000 |
| Net Common Stock Issuance | $87,784,000 | $128,840,000 | $52,081,000 | $45,344,000 |
| Common Stock Issuance | $87,784,000 | $128,840,000 | $52,081,000 | $45,344,000 |
| Net Other Financing Charges | - | - | - | $1,000 |
| Other | ||||
| End Cash Position | $84,941,000 | $128,779,000 | $192,011,000 | $114,125,000 |
| Beginning Cash Position | $128,779,000 | $192,011,000 | $114,125,000 | $145,464,000 |
| Changes In Cash | $-43,838,000 | $-63,232,000 | $77,886,000 | $-31,339,000 |
| Proceeds From Stock Option Exercised | $9,605,000 | $2,254,000 | $926,000 | $1,064,000 |
| Net Investment Purchase And Sale | $-186,142,000 | $-107,272,000 | $107,562,000 | $-41,920,000 |
| Sale Of Investment | $136,580,000 | $60,000,000 | $107,562,000 | $159,400,000 |
| Purchase Of Investment | $-322,722,000 | $-167,272,000 | $0 | $-201,320,000 |
| Net PPE Purchase And Sale | $-670,000 | $-203,000 | $-1,616,000 | $-3,962,000 |
| Purchase Of PPE | $-670,000 | $-203,000 | $-1,616,000 | $-3,962,000 |
| Change In Working Capital | $16,346,000 | $-28,140,000 | $-6,030,000 | $43,023,000 |
| Change In Other Working Capital | $-130,000 | $-29,392,000 | $-3,351,000 | $51,736,000 |
| Change In Payables And Accrued Expense | $21,289,000 | $3,088,000 | $-3,208,000 | $-3,530,000 |
| Change In Prepaid Assets | $-545,000 | $-1,786,000 | $529,000 | $-5,183,000 |
| Change In Receivables | $-4,268,000 | $-50,000 | - | - |
| Changes In Account Receivables | $-4,268,000 | $-50,000 | - | - |
| Other Non Cash Items | $2,408,000 | $2,265,000 | $2,260,000 | $1,989,000 |
| Stock Based Compensation | $32,238,000 | $27,470,000 | $25,257,000 | $22,854,000 |
| Asset Impairment Charge | $696,000 | $0 | - | - |
| Amortization Of Securities | $-1,133,000 | $-1,642,000 | $-325,000 | $-211,000 |
| Depreciation Amortization Depletion | $1,770,000 | $2,177,000 | $2,469,000 | $1,546,000 |
| Depreciation And Amortization | $1,770,000 | $2,177,000 | $2,469,000 | $1,546,000 |
| Depreciation | $1,770,000 | $2,177,000 | $2,469,000 | $1,546,000 |
| Gain Loss On Sale Of PPE | $145,000 | $0 | $1,000 | $0 |
| Net Income From Continuing Operations | $-6,885,000 | $-88,981,000 | $-104,699,000 | $-101,067,000 |
Fetched: 2026-06-16